Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled 'Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%; EBITDA at Rs 723 Cr, Up 35%; Core EBITDA at Rs 1,069 Cr, Up 49%; Net Profit (excluding exceptional items) at Rs 140 Cr' pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter and nine-months ended December 31, 2022. The above information will also be available on the website of the Company at www.biocon.com.
14-02-2023
Bigul

BIOCON LTD. - 532523 - Disclosure Under Regulation 30 Of SEBI Listing Regulations, 2015 - Amendment In The Policy For Determination Of Materiality For Disclosures

 Pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations, 2015'), the Board of Directors at its meeting held today i.e. on February 14, 2023 has approved amendment in the Policy for Determination of Materiality for Disclosures, and below mentioned Key Managerial Personnel(s) have been authorized to determine materiality of an event or information and make necessary disclosures to the Stock Exchange(s): The revised policy on determination of materiality of events and information of the Company is available on the website of the Company.
14-02-2023
Bigul

BIOCON LTD. - 532523 - Outcome Of Board Meeting Held On February 14, 2023

 Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors at its meeting held today, i.e. on Tuesday, February 14, 2023 has approved the un-audited financial results (standalone and consolidated) of the Company prepared as per Indian Accounting Standard (Ind-AS) along with Limited Review Report thereon for the quarter and nine-months ended December 31, 2022. A copy of the unaudited financial results along with the Limited Review Report and is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com. Further, the Board Meeting commenced at 3:30 p.m. and concluded at 6:50 p.m. Kindly take the above information on record and acknowledge.
14-02-2023
Bigul

BIOCON LTD. - 532523 - Board Meeting Outcome for Outcome Of The Board Meeting Held On February 14, 2023

 Pursuant to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors at its meeting held today, i.e. on Tuesday, February 14, 2023 has approved the un-audited financial results (standalone and consolidated) of the Company prepared as per Indian Accounting Standard (Ind-AS) along with Limited Review Report thereon for the quarter and nine-months ended December 31, 2022. A copy of the unaudited financial results along with the Limited Review Report and is enclosed herewith. The above information will also be available on the website of the Company at www.biocon.com. Further, the Board Meeting commenced at 3:30 p.m. and concluded at 6:50 p.m. Kindly take the above information on record and acknowledge.
14-02-2023
Bigul

BIOCON LTD. - 532523 - Certificate Pursuant To SEBI Circular No. SEBI/HO/DDHS/P/CIR/2021/613 Dated 10Th August 2021

 In terms of Chapter XVII of the SEBI Circular no. SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021, on Operational Circular for issue and listing of Non-convertible Securities, Securitised Debt Instruments, Security Receipts, Municipal Debt Securities and Commercial Paper, as amended from time to time, please find enclosed a quarterly certificate confirming the use of Commercial Paper proceeds and adherence to other listing conditions, for the quarter ended 31st December, 2022.
13-02-2023

MSCI revision: CG Power, Bank Baroda look bullish on charts; avoid Biocon

 Biocon share may slip up to 21 per cent if breaks 52-week low
13-02-2023
Bigul

BIOCON LTD. - 532523 - Company Statement

 Please find below a Company Statement. 'The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for Bevacizumab filed by our partner Viatris (Mylan). The CRL informs the need for a satisfactory resolution of the observations made during the facility inspection conducted in August, 2022. We have submitted a comprehensive Corrective and Preventive Action (CAPA) plan, to the agency and are confident of addressing the observations within the stipulated timeframe. The CRL did not identify any outstanding scientific issues with the dossier.'- Company Spokesperson, Biocon Biologics The above information will also be available on the website of the Company at www.biocon.com.
12-02-2023
Bigul

BIOCON LTD. - 532523 - Record Date Intimation For Commercial Papers

 We hereby inform the 'Record Date' for maturity of the Commercial Paper issued by the Company as follows: Issue Size : Rs. 2,250 Crore ISIN :INE376G14016 Maturity Date :February 22, 2023 Record Date :February 21, 2023 Listed/Unlisted :Listed on National Stock Exchange of India Limited
09-02-2023
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations), we wish to inform you that India Ratings and Research (Ind-Ra) has vide letters dated February 07, 2023 affirmed / assigned the ratings for the following instrumnets- 1. Long-term issuer rating 2. Proposed non-convertible debentures (NCDs) 3. Term loans-External Commercial Borrowings (ECBs) 4. Proposed term loans 5. Commercial Paper (CP)
08-02-2023

Biocon sells 9.96% stake in contract research firm Syngene via open market

 Bengaluru-based Biocon had in September 2022 sold a 5.4% stake in the open market, as per an exchange filing
01-02-2023
Next Page
Close

Let's Open Free Demat Account